-
公开(公告)号：US11083705B2
公开(公告)日：2021-08-10
申请号：US16835719
申请日：2020-03-31
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yasuhiro Funahashi
IPC: A61K31/357 , A61K9/127 , A61P35/00 , C07K16/28 , A61P35/04
Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
-
公开(公告)号：US20140148483A1
公开(公告)日：2014-05-29
申请号：US14117276
申请日：2012-05-16
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
CPC classification number: C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
Abstract translation: 本发明的目的是提供一种用于预测患有肿瘤的受试者中血管生成抑制剂的有效性的方法。 提供了一种方法，其包括测试来自受试者的肿瘤组织样品中是否存在B-Raf和PTEN的突变或丧失的表达的存在或不存在的步骤。 通过使用B-Raf和PTEN的表达的存在或不存在或突变或丧失作为指标，该方法能够预测血管生成抑制剂的抗肿瘤效力，而不向受试者施用血管生成抑制剂。
-
公开(公告)号：US12036204B2
公开(公告)日：2024-07-16
申请号：US17563162
申请日：2021-12-28
Inventor： Taro Semba , Yasuhiro Funahashi , Takuya Suzuki
IPC: A61K31/357 , A61K39/395 , A61P35/00
CPC classification number: A61K31/357 , A61K39/3955 , A61P35/00
Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
-
Patent Agency Ranking
公开(公告)号：US20210177802A1
公开(公告)日：2021-06-17
申请号：US17180107
申请日：2021-02-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yasuhiro Funahashi
IPC: A61K31/357 , A61P35/04 , C07K16/28
Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
-
公开(公告)号：US20210023047A1
公开(公告)日：2021-01-28
申请号：US16835719
申请日：2020-03-31
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yasuhiro Funahashi
IPC: A61K31/357 , C07K16/28 , A61P35/04
Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof
-
公开(公告)号：US20230212679A1
公开(公告)日：2023-07-06
申请号：US17692698
申请日：2022-03-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
IPC: C12Q1/6886 , A61K31/47 , G01N33/574 , A61K31/517 , A61K31/404 , A61K31/4025
CPC classification number: C12Q1/6886 , A61K31/47 , A61K31/404 , A61K31/517 , A61K31/4025 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , C12Q2600/16 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N2333/82 , G01N2333/515 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
-
公开(公告)号：US20220117933A1
公开(公告)日：2022-04-21
申请号：US17563162
申请日：2021-12-28
Inventor： Taro Semba , Yasuhiro Funahashi , Takuya Suzuki
IPC: A61K31/357 , A61K39/395 , A61P35/00
Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
-
公开(公告)号：US20170191137A1
公开(公告)日：2017-07-06
申请号：US15460629
申请日：2017-03-16
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
IPC: C12Q1/68 , G01N33/574 , A61K31/47
CPC classification number: C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
